Tackling underlying respiratory conditions for this pandemic and next

During the COVID-19 pandemic, one of the many phrases that has become irreversibly etched onto the minds of the British public – along with…

Infex partners with Alderley Analytical to provide PK and ADA analysis for RESP-X program

Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and ADA analysis of Infex’s RESP-X program.

Deals agreed as Infex’s resistance bypass drug program heads for clinic

Infex Therapeutics has appointed Pharmaron to help progress its MET-X program which targets urinary tract infections caused by WHO…

Infex focuses on pandemic preparedness with Covid patent

Infex Therapeutics has filed for a UK patent for a novel therapy designed to tackle all coronavirus strains.

Introducing Infex Therapeutics

The organisation leading UK efforts to tackle the health crisis around our dwindling supply of effective antibiotics is broadening its…

Major boost in global fight against antimicrobial resistance as AMR Centre receives share of Strength in Places Fund award

The AMR Centre has combined forces to attract much needed investment to combat the global threat of antimicrobial resistance (AMR)…

The AMR Centre signs agreement to co-develop treatment for gonorrhoea

The AMR Centre (AMRC) has today announced a multi-year co-development agreement with Massachusetts-based clinical stage biopharmaceutical…

A Deal to Fix the Broken Antibiotic Market?

The market for new antibiotics is effectively failing.